ARTICLE | Company News
Advaxis, BMS partner to evaluate ADXS-DUAL plus Opdivo in cervical cancer
May 31, 2017 10:05 PM UTC
Advaxis Inc. (NASDAQ:ADXS) will sponsor a clinical trial evaluating its ADXS-DUAL in combination with PD-1 inhibitor Opdivo nivolumab to treat metastatic cervical cancer. The trial is slated to start this year...